<article article-type="review-article" dtd-version="1.4" id="jvh70152" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Viral Hepat</journal-id><journal-id journal-id-type="iso-abbrev">J Viral Hepat</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">JVH</journal-id><journal-title-group><journal-title>Journal of Viral Hepatitis</journal-title></journal-title-group><issn pub-type="ppub">1352-0504</issn><issn pub-type="epub">1365-2893</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12923650</article-id><article-id pub-id-type="pmcid-ver">PMC12923650.1</article-id><article-id pub-id-type="pmcaid">12923650</article-id><article-id pub-id-type="pmcaiid">12923650</article-id><article-id pub-id-type="pmid">41721452</article-id><article-id pub-id-type="doi">10.1111/jvh.70152</article-id><article-id pub-id-type="publisher-id">JVH70152</article-id><article-id pub-id-type="other">5097494</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hepatitis E Infection in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta‐Analysis</article-title></title-group><contrib-group><contrib contrib-type="author" id="jvh70152-cr-0001"><name name-style="western"><surname>Kogias</surname><given-names initials="D">Dionysios</given-names></name><xref ref-type="aff" rid="jvh70152-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes" id="jvh70152-cr-0002"><name name-style="western"><surname>Kouklakis</surname><given-names initials="G">Georgios</given-names></name><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-5961-9981</contrib-id><xref ref-type="aff" rid="jvh70152-aff-0001">
<sup>1</sup>
</xref><address><email>gkouklak@med.duth.gr</email></address></contrib><contrib contrib-type="author" id="jvh70152-cr-0003"><name name-style="western"><surname>Papadopoulos</surname><given-names initials="V">Vasileios</given-names></name><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-4188-9518</contrib-id><xref ref-type="aff" rid="jvh70152-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jvh70152-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">First Department of Internal Medicine, Department of Medicine</named-content>
<institution>Democritus University of Thrace</institution>
<city>Alexandroupolis</city>
<country country="GR">Greece</country>
</aff><aff id="jvh70152-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Anatomy, Department of Medicine</named-content>
<institution>Democritus University of Thrace</institution>
<city>Alexandroupolis</city>
<country country="GR">Greece</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Georgios Kouklakis (<email>gkouklak@med.duth.gr</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2026</year></pub-date><volume>33</volume><issue seq="140">3</issue><issue-id pub-id-type="pmc-issue-id">508060</issue-id><issue-id pub-id-type="doi">10.1111/jvh.v33.3</issue-id><elocation-id>e70152</elocation-id><history><date date-type="rev-recd"><day>08</day><month>10</month><year>2025</year></date><date date-type="received"><day>03</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>22</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-22 00:25:13.403"><day>22</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2026 The Author(s). <italic toggle="yes">Journal of Viral Hepatitis</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="JVH-33-0.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri content-type="pdf" xlink:href="file:JVH-33-0.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>ABSTRACT</title><p>Opportunistic infections are increasingly recognised in patients with inflammatory bowel disease (IBD), particularly among those receiving immunosuppressive therapy. Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide, yet its relevance in IBD remains insufficiently clarified. This systematic review and meta‐analysis aimed to explore the association between HEV infection and IBD. A comprehensive literature search was performed in PubMed/MEDLINE and Google Scholar up to May 2025, identifying all studies reporting HEV infection in patients with ulcerative colitis (UC) or Crohn's disease (CD), with or without a control group. Study quality was assessed using the Joanna Briggs Institute Checklist for Analytical Cross‐Sectional Studies. Six eligible studies encompassing 1316 IBD patients were included in the qualitative and quantitative synthesis. The pooled prevalence of anti‐HEV IgG (HEV‐G) antibodies among IBD patients was 13.5%, though with notable heterogeneity. Anti‐HEV IgM (HEV‐M) and HEV‐RNA positivity rates were significantly lower, at 1.9% and 0.03%, respectively. When compared with the general population, IBD patients exhibited similar HEV‐G and HEV‐M prevalence, and comparable rates were observed between UC and CD subgroups. In contrast, immunocompromised transplant recipients demonstrated markedly higher HEV seropositivity. Sensitivity analyses confined to European cohorts indicated a modest rise in HEV‐G and HEV‐M levels, particularly among patients receiving intensified immunosuppression. Clinically, unexplained elevations of liver enzymes in IBD should prompt consideration of HEV infection. Overall, HEV prevalence in IBD parallels that of the general population; however, severe immunosuppression may predispose to persistent infection or liver‐related complications, warranting routine testing for accurate diagnosis.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jvh70152-kwd-0001">crohn's disease</kwd><kwd id="jvh70152-kwd-0002">hepatitis E</kwd><kwd id="jvh70152-kwd-0003">immunosuppression</kwd><kwd id="jvh70152-kwd-0004">inflammatory bowel disease</kwd><kwd id="jvh70152-kwd-0005">ulcerative colitis</kwd></kwd-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="8"/><word-count count="5200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.7.1 mode:remove_FC converted:20.02.2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="jvh70152-body-0001"><def-list id="jvh70152-dl-0001" list-content="abbreviations"><title>Abbreviations</title><def-item><term id="jvh70152-li-0001">ALP</term><def id="jvh70152-li-0002"><p>alkaline phosphatase</p></def></def-item><def-item><term id="jvh70152-li-0003">ALT</term><def id="jvh70152-li-0004"><p>alanine transaminase</p></def></def-item><def-item><term id="jvh70152-li-0005">AST</term><def id="jvh70152-li-0006"><p>aspartate transferase</p></def></def-item><def-item><term id="jvh70152-li-0007">CD</term><def id="jvh70152-li-0008"><p>Crohn's disease</p></def></def-item><def-item><term id="jvh70152-li-0009">CRP</term><def id="jvh70152-li-0010"><p>C‐reactive protein</p></def></def-item><def-item><term id="jvh70152-li-0011">DBIL</term><def id="jvh70152-li-0012"><p>direct bilirubin</p></def></def-item><def-item><term id="jvh70152-li-0013">DILI</term><def id="jvh70152-li-0014"><p>drug‐induced liver injury</p></def></def-item><def-item><term id="jvh70152-li-0015">EASL</term><def id="jvh70152-li-0016"><p>European Association for the Study of the Liver</p></def></def-item><def-item><term id="jvh70152-li-0017">GBD</term><def id="jvh70152-li-0018"><p>Global Burden of Disease</p></def></def-item><def-item><term id="jvh70152-li-0019">GGT</term><def id="jvh70152-li-0020"><p>gamma‐glutamyl transferase</p></def></def-item><def-item><term id="jvh70152-li-0021">HEV</term><def id="jvh70152-li-0022"><p>hepatitis E virus</p></def></def-item><def-item><term id="jvh70152-li-0023">HEV‐G</term><def id="jvh70152-li-0024"><p>anti‐HEV IgG antibodies</p></def></def-item><def-item><term id="jvh70152-li-0025">HEV‐M</term><def id="jvh70152-li-0026"><p>anti‐HEV IgM antibodies</p></def></def-item><def-item><term id="jvh70152-li-0027">HEV RNA</term><def id="jvh70152-li-0028"><p>hepatitis E virus ribonucleic acid</p></def></def-item><def-item><term id="jvh70152-li-0029">IBD</term><def id="jvh70152-li-0030"><p>inflammatory bowel disease</p></def></def-item><def-item><term id="jvh70152-li-0031">NAT</term><def id="jvh70152-li-0032"><p>nucleic acid tests</p></def></def-item><def-item><term id="jvh70152-li-0033">PSC</term><def id="jvh70152-li-0034"><p>primary sclerosing cholangitis</p></def></def-item><def-item><term id="jvh70152-li-0035">RBV</term><def id="jvh70152-li-0036"><p>ribavirin</p></def></def-item><def-item><term id="jvh70152-li-0037">RNA</term><def id="jvh70152-li-0038"><p>ribonucleic acid</p></def></def-item><def-item><term id="jvh70152-li-0039">RT‐PCR</term><def id="jvh70152-li-0040"><p>real‐time polymerase chain reaction</p></def></def-item><def-item><term id="jvh70152-li-0041">SVR</term><def id="jvh70152-li-0042"><p>sustained virological response</p></def></def-item><def-item><term id="jvh70152-li-0043">TBIL</term><def id="jvh70152-li-0044"><p>total bilirubin</p></def></def-item><def-item><term id="jvh70152-li-0045">UC</term><def id="jvh70152-li-0046"><p>ulcerative colitis</p></def></def-item></def-list><sec id="jvh70152-sec-0001"><label>1</label><title>Introduction</title><p>Hepatitis E virus (HEV) is a single‐stranded RNA virus classified within the Hepeviridae family and is a primary cause of acute hepatitis, primarily transmitted via the faecal‐oral route. While historically recognised as a major cause of epidemic hepatitis in developing countries, HEV has recently emerged as a global public health concern. Phylogenetic analysis categorises HEV into eight genotypes (HEV1–8). HEV1 and HEV2 are exclusive to humans and are commonly linked to epidemics in developing regions due to inadequate hygiene and sanitation. HEV3 and HEV4 are zoonotic, primarily infecting animals such as pigs, wild boars, and deer, with human transmission occurring through the consumption of contaminated meat. These genotypes are prevalent in industrialised nations and are responsible for sporadic and clustered cases of hepatitis E. HEV5 and HEV6 have been identified only in wild boars, while HEV7 and HEV8 have been detected in camels. Notably, HEV7 has been reported in a small number of immunocompromised individuals following the consumption of camel meat and milk [<xref ref-type="bibr" rid="jvh70152-bib-0001">1</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0002">2</xref>].</p><p>The majority of HEV infections are asymptomatic or present with mild, self‐limiting symptoms, with most patients recovering without medical intervention [<xref ref-type="bibr" rid="jvh70152-bib-0003">3</xref>]. However, progression to chronic hepatitis E—defined as the inability to clear the virus within three months of initial infection—is uncommon and occurs primarily in immunocompromised individuals. Chronic HEV infection is most frequently associated with HEV3 and HEV4, with sporadic cases linked to HEV7 [<xref ref-type="bibr" rid="jvh70152-bib-0004">4</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0005">5</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0006">6</xref>]. Common risk factors for chronicity include immunosuppressive conditions, such as those affecting patients undergoing haemodialysis [<xref ref-type="bibr" rid="jvh70152-bib-0007">7</xref>], recipients of solid organ transplants, and individuals with haematological malignancies or autoimmune disorders receiving immunosuppressive therapy [<xref ref-type="bibr" rid="jvh70152-bib-0008">8</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0009">9</xref>].</p><p>Patients with inflammatory bowel disease (IBD) have an increased risk of infections due to immune system alterations resulting from the disease's pathophysiology and the use of immunomodulatory medications. Elevated liver enzyme levels are commonly observed in individuals with IBD and are primarily associated with nonalcoholic fatty liver disease, primary sclerosing cholangitis (PSC), or drug‐induced liver injury (DILI) [<xref ref-type="bibr" rid="jvh70152-bib-0010">10</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0011">11</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0012">12</xref>]. Several studies have investigated the prevalence of HEV infection among IBD patients, some with contradictory results [<xref ref-type="bibr" rid="jvh70152-bib-0013">13</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0014">14</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0015">15</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0016">16</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0017">17</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0018">18</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0019">19</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0020">20</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0021">21</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0022">22</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0023">23</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0024">24</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0025">25</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0026">26</xref>].</p><p>The present systematic literature review and meta‐analysis was conducted with the aim of providing further evidence about the prevalence of acute and chronic HEV infections in patients with IBD by identifying all relevant studies and summarising their results.</p></sec><sec id="jvh70152-sec-0002" sec-type="materials-and-methods"><label>2</label><title>Materials and Methods</title><sec id="jvh70152-sec-0003"><label>2.1</label><title>Literature Search</title><p>A systematic literature review was conducted using the PubMed/MEDLINE database until May 7, 2025 to identify all studies that reported HEV infection in patients with UC and CD. The SciELO and Google Scholar databases were used as an additional pool of published data. The search was performed independently by two authors (DK and VP). No automation tool was used. The PRSIMA guidelines were considered for reporting [<xref ref-type="bibr" rid="jvh70152-bib-0027">27</xref>].</p></sec><sec id="jvh70152-sec-0004"><label>2.2</label><title>Study Selection</title><p>The review was conducted using a search strategy that included the terms [inflammatory bowel disease] AND [hepatitis E virus]; [inflammatory bowel disease] AND [HEV]; [ulcerative colitis] AND [hepatitis E virus]; [ulcerative colitis] AND [HEV]; [crohn] AND [hepatitis E virus]; [crohn] AND [HEV]. No software was used for study retrieval.</p><p>A study was considered eligible if: (a) referred to adult patients; (b) reported at least one outcome measure; and (c) contained at least an English abstract. Exclusion criteria included: (a) publications in forms of case reports, narrative reviews, and editorials. The selection was performed independently by two authors (DK and VP). Any dispute was resolved by a third author (GK).</p></sec><sec id="jvh70152-sec-0005"><label>2.3</label><title>Outcome Measures</title><p>PICO (P—Populations/People/Patient/Problem: Patients suffering from any type of IBD (UC and CD), sex‐ and age‐adjusted healthy individuals (healthy controls), and immunocompromised patients (immunocompromised controls); I—Intervention(s): HEV infection; C—Comparison: (i) prevalence of HEV IgG and IgM antibodies and HEV RNA positive value among patients suffering from CD compared with UC; (ii) prevalence of HEV‐G, HEV‐M, and HEV RNA positive value among IBD patients and healthy controls; (iii) prevalence of HEV IgG and IgM antibodies and HEV RNA positive value among IBD patients and immunocompromised controls; O—Outcome: OR; percentage) worksheet and search strategy.</p><p>HEV‐related outcome in IBD patients measures data were compared with the meta‐analysis of Li et al. [<xref ref-type="bibr" rid="jvh70152-bib-0028">28</xref>] for general population, while data from the meta‐analysis of Buescher et al. were used to compare outcome measures between IBD patients and immunocompromised patients [<xref ref-type="bibr" rid="jvh70152-bib-0029">29</xref>].</p></sec><sec id="jvh70152-sec-0006"><label>2.4</label><title>Data Acquisition</title><p>For every included study, all relevant data concerning the name of the first author, the year that the study was conducted, the country that the publication derived from, the number of patients included, the male ratio of the patients, the mean age and the standard deviation of the patients, and the HEV‐G, HEV‐M, and HEV‐RNA positives among analysed samples were collected. In any case that IBD patients were reported, discrimination between CD and UC was recorded.</p></sec><sec id="jvh70152-sec-0007"><label>2.5</label><title>Quality Assessment</title><p>The Johanna Briggs Institute (JBI) Checklist for Analytical Cross‐Sectional Studies was used [<xref ref-type="bibr" rid="jvh70152-bib-0030">30</xref>]. In detail, eight elements (domains) were assessed by the respective questions, namely, Q1: “Were the criteria for inclusion in the sample clearly defined?”; Q2: “Were the study subjects and the setting described in detail?”; Q3: “Was the exposure measured in a valid and reliable way?”; Q4:“Were objective, standard criteria used for measurement of the condition?”; Q5: “Were confounding factors identified?”; Q6: “Were strategies to deal with confounding factors stated?”; Q7: “Were the outcomes measured in a valid and reliable way?”; Q8: “Was appropriate statistical analysis used?” For each element, a response was recorded as “Yes” (Y), “No” (N), “Unclear (U),” and “Not Applicable” (NA) accordingly. A study was considered of acceptable quality if negative responses were ≤ 25% of the total elements assessed.</p></sec><sec id="jvh70152-sec-0008"><label>2.6</label><title>Evidence Synthesis</title><p>Data were analysed using STATA 19 and RevMan 5.3. Means and standard deviations (SDs) were combined using an online tool (<ext-link ext-link-type="uri" xlink:href="https://www.statstodo.com/CombineMeansSDs.php" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.statstodo.com/CombineMeansSDs.php</ext-link>, accessed 7 May 2025), while estimates based on sample size, median, range, and interquartile range were derived using another online tool (<ext-link ext-link-type="uri" xlink:href="https://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html</ext-link>, accessed 7 May 2025). Heterogeneity was assessed using the Q test (<italic toggle="yes">p</italic> &lt; 0.10 indicating significance) and the I<sup>2</sup> statistic (≤ 25%: insignificant; 26%–50%: low; 51%–75%: moderate; &gt; 75%: high). Prevalence and proportion data were pooled implementing Freeman–Tukey double arcsine transformation. A random‐effects model was used when I<sup>2</sup> &gt; 50, else a fixed‐effects model was preferred. A Galbraith plot identified potential outliers. Publication bias was evaluated via funnel plot symmetry, supported by Egger's and Begg's tests, with the trim‐and‐fill method used to adjust for missing studies. Sensitivity analysis was conducted using a leave‐one‐out approach to examine the impact of individual studies on heterogeneity. Subgroup analysis was further used to investigate potential sources of heterogeneity.</p></sec></sec><sec id="jvh70152-sec-0009" sec-type="results"><label>3</label><title>Results</title><sec id="jvh70152-sec-0010"><label>3.1</label><title>Literature Search / Study Selection / Quality Assessment</title><p>In total, 77 studies were identified. After removal of the 20 duplicates, the remaining 57 studies were considered for eligibility by title/abstract, and 13 were further judged based on full text. Six studies fulfilled the eligibility criteria and were qualitatively and quantitatively analysed (Table <xref ref-type="table" rid="jvh70152-tbl-0001">1</xref>, Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0002">SS1</xref>). The quality assessment is analytically presented in Supplementary Table <xref ref-type="supplementary-material" rid="jvh70152-supitem-0012">S1</xref>.</p><table-wrap content-type="TABLE" id="jvh70152-tbl-0001" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Included studies; HL‐IT: High‐level immunosuppression therapy rate.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="1" rowspan="1" valign="bottom">Study<xref ref-type="table-fn" rid="jvh70152-note-0001">
<sup>†</sup>
</xref>
</th><th align="center" colspan="1" rowspan="1" valign="bottom">Region</th><th align="center" colspan="1" rowspan="1" valign="bottom">HL‐IT</th><th align="center" colspan="1" rowspan="1" valign="bottom">Patients (CD/UC)</th><th align="center" colspan="1" rowspan="1" valign="bottom">Male ratio</th><th align="center" colspan="1" rowspan="1" valign="bottom">Mean Age (SD)</th><th align="center" colspan="1" rowspan="1" valign="bottom">Anti‐HEV IgG (CD/UC)</th><th align="center" colspan="1" rowspan="1" valign="bottom">Anti‐HEV IgM (CD/UC)</th><th align="center" colspan="1" rowspan="1" valign="bottom">HEV‐RNA (CD/UC)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1" valign="top">Senosiain, 2015, [<xref ref-type="bibr" rid="jvh70152-bib-0013">13</xref>]</td><td align="center" colspan="1" rowspan="1" valign="top">Spain</td><td align="center" colspan="1" rowspan="1" valign="top">0.517</td><td align="center" colspan="1" rowspan="1" valign="top">87 (50/36)<xref ref-type="table-fn" rid="jvh70152-note-0002">
<sup>‡</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1" valign="top">0.552</td><td align="center" colspan="1" rowspan="1" valign="top">44.7 (16.0)</td><td align="center" colspan="1" rowspan="1" valign="top">1/80 (1/0)</td><td align="center" colspan="1" rowspan="1" valign="top">2/75 (2/0)</td><td align="center" colspan="1" rowspan="1" valign="top">0/46</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Garrido, 2019, [<xref ref-type="bibr" rid="jvh70152-bib-0014">14</xref>]</td><td align="center" colspan="1" rowspan="1" valign="top">Portugal</td><td align="center" colspan="1" rowspan="1" valign="top">0.823</td><td align="center" colspan="1" rowspan="1" valign="top">62 (57/5)</td><td align="center" colspan="1" rowspan="1" valign="top">0.516</td><td align="center" colspan="1" rowspan="1" valign="top">48.8 (14.6)</td><td align="center" colspan="1" rowspan="1" valign="top">22/62</td><td align="center" colspan="1" rowspan="1" valign="top">—</td><td align="center" colspan="1" rowspan="1" valign="top">—</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Hoffmann, 2020, [<xref ref-type="bibr" rid="jvh70152-bib-0015">15</xref>]</td><td align="center" colspan="1" rowspan="1" valign="top">Germany</td><td align="center" colspan="1" rowspan="1" valign="top">0.841</td><td align="center" colspan="1" rowspan="1" valign="top">478 (328/150)</td><td align="center" colspan="1" rowspan="1" valign="top">0.477</td><td align="center" colspan="1" rowspan="1" valign="top">44.3 (10.4)</td><td align="center" colspan="1" rowspan="1" valign="top">94/478 (57/37)</td><td align="center" colspan="1" rowspan="1" valign="top">—</td><td align="center" colspan="1" rowspan="1" valign="top">0/478</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Grigas, 2021, [<xref ref-type="bibr" rid="jvh70152-bib-0016">16</xref>]</td><td align="center" colspan="1" rowspan="1" valign="top">Lithuania</td><td align="center" colspan="1" rowspan="1" valign="top">0.207</td><td align="center" colspan="1" rowspan="1" valign="top">203 (47/156)</td><td align="center" colspan="1" rowspan="1" valign="top">0.581</td><td align="center" colspan="1" rowspan="1" valign="top">40.0 (15.0)</td><td align="center" colspan="1" rowspan="1" valign="top">25/203 (6/19)</td><td align="center" colspan="1" rowspan="1" valign="top">13/203 (4/9)</td><td align="center" colspan="1" rowspan="1" valign="top">1/203 (0/1)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Kounis, 2023, [<xref ref-type="bibr" rid="jvh70152-bib-0017">17</xref>]</td><td align="center" colspan="1" rowspan="1" valign="top">France</td><td align="center" colspan="1" rowspan="1" valign="top">1.000</td><td align="center" colspan="1" rowspan="1" valign="top">488 (327/161)</td><td align="center" colspan="1" rowspan="1" valign="top">0.508</td><td align="center" colspan="1" rowspan="1" valign="top">41.7 (14.7)</td><td align="center" colspan="1" rowspan="1" valign="top">69/488 (46/21)</td><td align="center" colspan="1" rowspan="1" valign="top">3/488</td><td align="center" colspan="1" rowspan="1" valign="top">0/488</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Santos, 2023, [<xref ref-type="bibr" rid="jvh70152-bib-0018">18</xref>]</td><td align="center" colspan="1" rowspan="1" valign="top">Brazil</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top">38</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top">3/38</td><td align="center" colspan="1" rowspan="1" valign="top">0/38 (0/0)</td><td align="center" colspan="1" rowspan="1" valign="top"/></tr></tbody></table><table-wrap-foot id="jvh70152-ntgp-0001"><fn id="jvh70152-note-0001"><label>
<sup>†</sup>
</label><p>All studies were cross‐sectional.</p></fn><fn id="jvh70152-note-0002"><label>
<sup>‡</sup>
</label><p>One patient had undetermined colitis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jvh70152-sec-0011"><label>3.2</label><title>Synthesis</title><p>Among IBD patients, the pooled prevalence of HEV‐G antibodies was 13.5% (95% CI: 5.8–23.7) with considerable heterogeneity (I<sup>2</sup> = 94.8%) (Figure <xref ref-type="fig" rid="jvh70152-fig-0001">1</xref>). Moreover, the pooled prevalence of HEV‐M and HEV‐RNA was 1.9% (95% CI: 0.0–5.5; I<sup>2</sup> = 79.2%) (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0003">SS2</xref>) and 0.03% (95% CI: 0.00–0.20; I<sup>2</sup> = 0.0%), respectively (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0004">SS3</xref>).</p><fig fig-type="FIGURE" id="jvh70152-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>HEV‐G prevalence among IBD patients; forest plot.</p></caption><graphic id="jats-graphic-1" orientation="portrait" position="anchor" xlink:href="JVH-33-0-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>When IBD patients are compared with the general population, using a pooled estimate from 287 studies [<xref ref-type="bibr" rid="jvh70152-bib-0028">28</xref>], they present comparable HEV‐G prevalence (13.5% (95% CI: 5.8–23.7) vs. 12.47% with 95% CI: 10.42–14.67; RR 1.08 with 95% CI: 0.55–2.14; <italic toggle="yes">p</italic> = 0.83). Similarly, the prevalence of HEV‐M in IBD patients is 1.9% (95% CI: 0.0–5.5), when compared to the general population (1.47%; 95% CI: 1.14–1.85; pooled data from 98 studies), yields an RR of 1.29 with 95% CI: 0.30–5.58 (<italic toggle="yes">p</italic> = 0.76) for acute HEV infection. Lastly, HEV‐RNA is comparable (<italic toggle="yes">p</italic> = 0.06) between IBD patients (0.03%; 95% CI: 0.00–0.20) and healthy individuals (0.20%; 95% CI: 0.15–0.25).</p><p>Of note, the prevalence of HEV‐G among CD (11.5%; 95% CI: 5.6–19.1; Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0005">SS4</xref>) and UC (11.0%; 95% CI: 2.6–23.7; Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0006">SS5</xref>) patients is comparable (RR 0.85; 95% CI: 0.65–1.12; I<sup>2</sup> 0%; <italic toggle="yes">p</italic> = 0.25; Figure <xref ref-type="fig" rid="jvh70152-fig-0002">2</xref>). However, concerning HEV‐M and HEV‐RNA, data are insufficient for direct comparison.</p><fig fig-type="FIGURE" id="jvh70152-fig-0002" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>Comparison between HEV‐G prevalence among CD and UC patients; forest plot.</p></caption><graphic id="jats-graphic-3" orientation="portrait" position="anchor" xlink:href="JVH-33-0-g003.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Among transplanted immunocompromised patients, HEV‐G are more prevalent (23.4%–36.5%) than IBD patients (16.8; <italic toggle="yes">p</italic> &lt; 0.05). Similarly, HEV‐RNA is strikingly more prevalent among transplanted patients (0.95%–2.08%) than among IBD patients (0.08; <italic toggle="yes">p</italic> &lt; 0.001). In detail, HEV‐G prevalence comparison between IBD patients and immunocompromised patients and relevant data regarding HEV‐RNA are provided in Table <xref ref-type="table" rid="jvh70152-tbl-0002">2</xref>.</p><table-wrap content-type="TABLE" id="jvh70152-tbl-0002" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>A, RR of anti‐HEV IgG prevalence in immunocompromised vs. IBD patients; B, RR of active viremia (HEV‐RNA positive) in immunocompromised vs. IBD patients.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="1" rowspan="1" valign="bottom">Group</th><th align="center" colspan="1" rowspan="1" valign="bottom">Prevalence</th><th align="center" colspan="1" rowspan="1" valign="bottom">RR; 95% CI (vs. IBD)</th><th align="center" colspan="1" rowspan="1" valign="bottom">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1" valign="top">A</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">IBD patients (pooled)</td><td align="center" colspan="1" rowspan="1" valign="top">13.5 (5.8–23.7)</td><td align="center" colspan="1" rowspan="1" valign="top">1.00 (reference)</td><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Kidney‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">33.9 (24.0–45.6)</td><td align="center" colspan="1" rowspan="1" valign="top">2.51 (1.48–3.78)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Liver‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">27.4 (18.3–38.9)</td><td align="center" colspan="1" rowspan="1" valign="top">2.03 (1.33–3.10)</td><td align="center" colspan="1" rowspan="1" valign="top">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Heart‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">36.5 (20.2–56.6)</td><td align="center" colspan="1" rowspan="1" valign="top">2.70 (1.48–4.94)</td><td align="center" colspan="1" rowspan="1" valign="top">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Lung‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">32.5 (11.8–63.3)</td><td align="center" colspan="1" rowspan="1" valign="top">2.41 (0.98–5.91)</td><td align="center" colspan="1" rowspan="1" valign="top">0.055</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Stem Cell‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">25.6 (13.2–43.9)</td><td align="center" colspan="1" rowspan="1" valign="top">1.90 (0.97–3.70)</td><td align="center" colspan="1" rowspan="1" valign="top">0.061</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">B</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">IBD patients (pooled)</td><td align="center" colspan="1" rowspan="1" valign="top">0.03 (0.00–0.20)</td><td align="center" colspan="1" rowspan="1" valign="top">1.00 (reference)</td><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Kidney‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">1.17 (0.68–2.00)</td><td align="center" colspan="1" rowspan="1" valign="top">39.0 (5.2–293)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Liver‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">0.95 (0.56–1.63)</td><td align="center" colspan="1" rowspan="1" valign="top">31.7 (4.2–239)</td><td align="center" colspan="1" rowspan="1" valign="top">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Lung‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">2.08 (0.69–6.08)</td><td align="center" colspan="1" rowspan="1" valign="top">69.3 (8.6–558)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Stem Cell‐transplanted patients</td><td align="center" colspan="1" rowspan="1" valign="top">1.28 (0.44–3.62)</td><td align="center" colspan="1" rowspan="1" valign="top">42.7 (5.3–342)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr></tbody></table></table-wrap></sec><sec id="jvh70152-sec-0012"><label>3.3</label><title>Heterogeneity Analysis</title><p>Applying a leave‐one‐out influence analysis suggests that none of the individual studies significantly influenced the pooled proportion when excluded (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0007">SS6</xref>).</p><p>Performing a sensitivity analysis by restricting results to European countries, the pooled prevalence of HEV‐G was 14.6% (95% CI: 5.5–27.0), while that of HEV‐M was 2.6% (95% CI: 0.0–7.9) (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0008">SS7</xref> and Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0009">SS8</xref>). Based on Europe‐specific prevalence of HEV‐G (9.31%; 95% CI: 7.35–11.48; 97 studies), and HEV‐M (0.79%; 95% CI: 0.30–1.51; 26 studies), as assessed by Li et al., IBD patients presented an increased, though nonsignificant, RR to be positive for HEV‐G (RR 1.57; 95% CI: 0.48–3.67; <italic toggle="yes">p</italic> = 0.34) and HEV‐M (RR 3.29; 95% CI: 0.00–26.33; <italic toggle="yes">p</italic> = 0.37).</p><p>Furthermore, when a subgroup analysis according to high‐level immunosuppression therapy rate (HL‐IT) was performed, IBD patients who administered HL‐IT ≥ 80% had increased HEV‐G when compared to those with &lt; 80% (21.6%; 95% CI: 11.3–34.0 vs. 5.8%; 95% CI: 0.0–20.6, Q‐test <italic toggle="yes">p</italic> = 0.08) (Figure <xref ref-type="fig" rid="jvh70152-fig-0003">3</xref>).</p><fig fig-type="FIGURE" id="jvh70152-fig-0003" orientation="portrait" position="float"><label>FIGURE 3</label><caption><p>Subgroup analysis according to high‐level immunosuppression therapy rate (HL‐IT); forest plot.</p></caption><graphic id="jats-graphic-5" orientation="portrait" position="anchor" xlink:href="JVH-33-0-g002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></sec><sec id="jvh70152-sec-0013"><label>3.4</label><title>Bias Assessment</title><p>The Galbraith plot does not suggest strong outliers (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0010">SS9</xref>). No publication bias was detected; there was no apparent funnel plot asymmetry. Moreover, applying trim‐and‐fill analysis, no imputed studies were observed (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0011">SS10</xref>). Additionally, both the Egger's and the Begg's test yielded non‐significant results (<italic toggle="yes">p</italic> = 0.805 and 1.000, respectively).</p></sec></sec><sec id="jvh70152-sec-0014" sec-type="discussion"><label>4</label><title>Discussion</title><p>It has been estimated that one‐third of the global population, representing over two billion people, live in HEV endemic areas at risk of infection [<xref ref-type="bibr" rid="jvh70152-bib-0028">28</xref>]. In fact, the true burden of hepatitis E remains largely unknown. To the best of our knowledge, this is the first systematic review and meta‐analysis concerning the relation between HEV infection and IBD and provides a comprehensive synthesis of the available evidence regarding the prevalence of HEV among patients with IBD. Our results suggest that the pooled seroprevalence of anti‐HEV IgG antibodies in IBD patients is 13.5%, which is comparable to that observed in the general population, with no statistically significant difference (RR 1.08; <italic toggle="yes">p</italic> = 0.83). This finding suggests that IBD itself may not confer an increased risk of HEV exposure or infection.</p><p>Similarly, the prevalence of markers of acute infection, including anti‐HEV IgM antibodies and HEV‐RNA, did not significantly differ between IBD patients and healthy controls. HEV‐M was detected in 1.9% of IBD patients, compared to 1.47% in the general population, with a non‐significant RR of 1.29 (<italic toggle="yes">p</italic> = 0.76). HEV‐RNA, indicative of active infection, was exceptionally rare among IBD patients (0.03%) and not significantly different from the general population (0.20%; <italic toggle="yes">p</italic> = 0.06) [<xref ref-type="bibr" rid="jvh70152-bib-0028">28</xref>].</p><p>Importantly, subgroup analysis revealed no significant differences in HEV‐G prevalence between CD and UC patients (11.5% vs. 11.0%, respectively; RR 0.85; <italic toggle="yes">p</italic> = 0.25), suggesting that disease subtype does not appear to influence HEV seropositivity. However, data were insufficient to make robust comparisons for HEV‐M and HEV‐RNA across CD and UC subgroups.</p><p>Immunosuppressive therapy offers significant therapeutic benefits in the management of IBD. Nevertheless, prolonged use of such treatments may be linked to an elevated risk of infections [<xref ref-type="bibr" rid="jvh70152-bib-0031">31</xref>]. Consequently, individuals with IBD receiving corticosteroids, immunosuppressants, or biological agents should be regarded as immunocompromised and susceptible to opportunistic infections [<xref ref-type="bibr" rid="jvh70152-bib-0032">32</xref>]. The prevalence and types of infections—including Hepatitis E—among IBD patients vary geographically, largely influenced by local endemic conditions. Analysing all six studies that were included in the present study, the majority of patients who had HEV infection received immunosuppressive therapy either with biologic agents or corticosteroids. However, several patients who had no previous treatment with immunomodulatory regimens were also infected by HEV. That indicated that, although the contribution of immunosuppressive therapy to infection susceptibility in IBD remains a subject of debate, infections represent a substantial burden for affected patients, and immunosuppression appears to play a contributory role [<xref ref-type="bibr" rid="jvh70152-bib-0033">33</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0034">34</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0035">35</xref>].</p><p>When comparing IBD patients to other immunocompromised populations, particularly transplant recipients, stark differences emerged. HEV‐G seroprevalence and HEV‐RNA positivity were significantly higher in transplant patients (23.4%–36.5% and 0.95%–2.08%, respectively) compared to IBD patients (16.8% and 0.08%, respectively; <italic toggle="yes">p</italic>‐values &lt; 0.05 and &lt; 0.001) (Table <xref ref-type="table" rid="jvh70152-tbl-0002">2</xref>) [<xref ref-type="bibr" rid="jvh70152-bib-0029">29</xref>]. These differences likely reflect the more profound and prolonged immunosuppression among transplant recipients compared to IBD populations. Considering potential risk factors for HEV infection—such as travel history, prior blood transfusions, and the consumption of seafood, wild boar, deer or pork—the available data remain limited. Specifically, Senosiain et al. reported that two of three HEV‐infected IBD patients had a history of consuming seafood and undercooked pork [<xref ref-type="bibr" rid="jvh70152-bib-0013">13</xref>]. Among the broader IBD cohort, 10 patients resided in rural areas, 29 had a history of travel, and 15 had received previous transfusions. Of the three patients infected with HEV, one had travelled to Morocco, and another had a history of transfusion. In a separate study, Kounis et al. investigated HEV infection in IBD patients undergoing immunosuppressive therapy and identified raw seafood consumption as the only statistically significant risk factor for HEV exposure [<xref ref-type="bibr" rid="jvh70152-bib-0017">17</xref>].</p><p>Our heterogeneity analysis highlighted substantial between‐study variability, particularly for HEV‐G, although sensitivity analyses, including a leave‐one‐out approach, confirmed the robustness of our estimates (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0007">SS6</xref>). Notably, restricting analyses to European cohorts yielded a slightly higher pooled prevalence of HEV‐G (14.6%) and HEV‐M (2.6%) among IBD patients. Yet, even in this region‐specific analysis, risk ratios comparing IBD patients with the general population remained nonsignificant (HEV‐G: RR 1.57, <italic toggle="yes">p</italic> = 0.34; HEV‐M: RR 3.29, <italic toggle="yes">p</italic> = 0.37), likely reflecting overlapping confidence intervals and limited power (Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0008">SS7</xref> and Figure <xref ref-type="supplementary-material" rid="jvh70152-supitem-0009">SS8</xref>).</p><p>Interestingly, patients undergoing high‐level immunosuppressive therapy (HL‐IT ≥ 80%) exhibited numerically higher HEV‐G prevalence (21.6%) compared to those with less frequent HL‐IT exposure (5.8%), although this difference did not reach conventional statistical significance (<italic toggle="yes">p</italic> = 0.08) (Figure <xref ref-type="fig" rid="jvh70152-fig-0003">3</xref>). These findings may warrant further investigation as they hint at a possible dose–response relationship between immunosuppression intensity and HEV exposure or reactivation risk.</p><p>Furthermore, an analysis of the eight case reports available in the literature revealed that seven patients were infected with genotype 3—commonly found in developed countries—while only one patient was infected with genotype 1, following travel to India [<xref ref-type="bibr" rid="jvh70152-bib-0019">19</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0020">20</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0021">21</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0022">22</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0023">23</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0024">24</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0025">25</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0026">26</xref>]. All eight patients were residing in Europe (seven in France and one in the Netherlands). Among them, two were transplant recipients undergoing immunosuppressive therapy, four were being treated with biologic agents, one was receiving azathioprine, and one was on mesalazine monotherapy. Regarding risk factors for HEV infection in these patients, the available data are limited. One patient infected with genotype 1 had a history of travel to India, while another patient infected with genotype 3 had consumed undercooked meat. Additionally, two patients had a history of prior blood transfusions.</p><p>Taken together, risk factors for HEV infection appear to play a significant role in determining susceptibility to the disease. Current prophylactic guidelines remain inadequate in preventing all clinically significant infections, particularly opportunistic ones. As a result, careful and continuous monitoring is crucial in the management of IBD patients undergoing immunosuppressive therapy.</p><p>Beyond seroprevalence, the clinical relevance of HEV infection in IBD lies primarily in its hepatic manifestations. Several studies have reported that HEV infection in IBD patients may lead to varying degrees of liver injury, ranging from transient elevation of transaminases to clinically significant hepatitis [<xref ref-type="bibr" rid="jvh70152-bib-0017">17</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0024">24</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0036">36</xref>]. In most cases, biochemical abnormalities such as raised ALT, AST, and GGT resolve spontaneously within a few weeks, consistent with the self‐limiting nature of HEV infection in immunocompetent individuals [<xref ref-type="bibr" rid="jvh70152-bib-0004">4</xref>]. However, in immunosuppressed IBD patients—particularly those treated with azathioprine, methotrexate, corticosteroids, or anti‐TNF agents—HEV may cause prolonged cholestasis, chronic hepatitis, or progressive hepatic fibrosis [<xref ref-type="bibr" rid="jvh70152-bib-0017">17</xref>, <xref ref-type="bibr" rid="jvh70152-bib-0037">37</xref>]. Chronic HEV infection, although uncommon, has been increasingly described in this population, emphasising the potential for viral persistence when immune control is impaired. Histopathological findings in such cases include portal inflammation, interface hepatitis, and variable degrees of fibrosis resembling autoimmune or drug‐induced liver injury [<xref ref-type="bibr" rid="jvh70152-bib-0036">36</xref>]. Because abnormal liver function tests are frequent in IBD and often attributed to hepatotoxic medication or primary sclerosing cholangitis, HEV infection should be considered in the differential diagnosis of any unexplained hepatic enzyme elevation. Systematic testing for HEV antibodies and HEV‐RNA could prevent diagnostic delays and unnecessary treatment discontinuations. Furthermore, as liver‐related morbidity may complicate the clinical course of IBD, early recognition and supportive management are crucial. The limited number of studies reporting detailed hepatic outcomes highlights an important research gap. Future prospective investigations should assess the natural history of HEV‐associated liver dysfunction in IBD and evaluate whether antiviral therapy or temporary withdrawal of immunosuppressive agents can optimise hepatic recovery and prevent chronic evolution.</p><p>Of note, there are some limitations of our study. First, the data analysed were derived from a limited number of cross‐sectional studies. Second, the substantial heterogeneity in HEV‐G estimates limits the precision of our pooled prevalence and suggests variability in study design, population characteristics, or serological assays. Second, while subgroup analyses were informative, some categories—particularly those concerning HEV‐M and HEV‐RNA—were limited by small sample sizes and underpowered comparisons. Third, geographic variation in HEV epidemiology and differential exposure risks may confound comparisons between IBD and general or immunocompromised populations. We were unable to perform a more detailed analysis of regional prevalence, genotype‐specific disease burden, or clinical outcomes as such information is currently available only through individual case reports.</p><p>In conclusion, the prevalence of HEV infection among IBD patients is similar to that of the general population, with no significant differences observed for HEV‐G, HEV‐M, or HEV‐RNA. There is no detectable difference in HEV seroprevalence between CD and UC, and any variation in HEV prevalence among IBD patients is most likely attributable to the degree of immunosuppressive therapy. This is further supported by the markedly higher HEV prevalence observed in transplant recipients and IBD patients receiving high‐level immunosuppression. These findings suggest that while IBD itself does not increase HEV risk, intensified immunosuppressive treatment may predispose to higher HEV exposure or reactivation. Clinicians should be aware of this potential risk in managing immunosuppressed IBD patients, particularly in regions with higher HEV prevalence. Routine HEV testing is recommended in unexplained hepatic dysfunction, as timely diagnosis prevents mismanagement and reduces the risk of persistent infection or progressive liver damage.</p></sec><sec id="jvh70152-sec-0016"><title>Funding</title><p>The authors have nothing to report.</p></sec><sec id="jvh70152-sec-0017" sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jvh70152-supitem-0001" orientation="portrait" position="float"><caption><p>
<bold>Data S1:</bold> Supplementary Legends.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s008.docx" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0002" orientation="portrait" position="float"><caption><p>
<bold>Figure S1:</bold> PRISMA 2020 flow diagram.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s006.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0003" orientation="portrait" position="float"><caption><p>
<bold>Figure S2:</bold> HEV‐M prevalence among IBD patients; forest plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s007.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0004" orientation="portrait" position="float"><caption><p>
<bold>Figure S3:</bold> HEV‐RNA prevalence among IBD patients; forest plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s010.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0005" orientation="portrait" position="float"><caption><p>
<bold>Figure S4:</bold> HEV‐G prevalence among CD patients; forest plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s001.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0006" orientation="portrait" position="float"><caption><p>
<bold>Figure S5:</bold> HEV‐G prevalence among UC patients; forest plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s012.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0007" orientation="portrait" position="float"><caption><p>
<bold>Figure S6:</bold> Leave‐one‐out influence analysis; forest plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s009.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0008" orientation="portrait" position="float"><caption><p>
<bold>Figure S7:</bold> Sensitivity analysis: European‐specific HEV‐G prevalence among IBD patients; forest plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s005.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0009" orientation="portrait" position="float"><caption><p>
<bold>Figure S8:</bold> Sensitivity analysis: European‐specific HEV‐M prevalence among IBD patients; forest plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s002.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0010" orientation="portrait" position="float"><caption><p>
<bold>Figure S9:</bold> Galbraith plot.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s003.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0011" orientation="portrait" position="float"><caption><p>
<bold>Figure S10:</bold> Funnel plot; no apparent asymmetry is observed, and no imputed studies are detected applying trim‐and‐fill analysis.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s011.tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="jvh70152-supitem-0012" orientation="portrait" position="float"><caption><p>
<bold>Table S1:</bold> Quality assessment of the included studies.</p></caption><media orientation="portrait" position="float" xlink:href="JVH-33-0-s004.docx" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material></sec></body><back><ack id="jvh70152-sec-0015"><title>Acknowledgements</title><p>Written informed consent has been obtained from the patient to publish this article. The publication of this article in OA mode was financially supported by HEAL‐Link.</p></ack><sec id="jvh70152-sec-0019" sec-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="jvh70152-bibl-0001"><title>References</title><ref id="jvh70152-bib-0001"><label>1</label><mixed-citation id="jvh70152-cit-0001" publication-type="journal">
<string-name name-style="western">
<given-names>M. A.</given-names>
<surname>Purdy</surname>
</string-name>, <string-name name-style="western">
<given-names>T. J.</given-names>
<surname>Harrison</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Jameel</surname>
</string-name>, et al., “<article-title>ICTV Virus Taxonomy Profile: Hepeviridae</article-title>,” <source>Journal of General Virology</source>
<volume>98</volume> (<year>2017</year>): <fpage>2645</fpage>–<lpage>2646</lpage>.<pub-id pub-id-type="pmid">29022866</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1099/jgv.0.000940</pub-id><pub-id pub-id-type="pmcid">PMC5718254</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0002"><label>2</label><mixed-citation id="jvh70152-cit-0002" publication-type="journal">
<string-name name-style="western">
<given-names>A. B.</given-names>
<surname>Brayne</surname>
</string-name>, <string-name name-style="western">
<given-names>B. L.</given-names>
<surname>Dearlove</surname>
</string-name>, <string-name name-style="western">
<given-names>J. S.</given-names>
<surname>Lester</surname>
</string-name>, <string-name name-style="western">
<given-names>S. L.</given-names>
<surname>Kosakovsky Pond</surname>
</string-name>, and <string-name name-style="western">
<given-names>S. D. W.</given-names>
<surname>Frost</surname>
</string-name>, “<article-title>Genotype‐Specific Evolution of Hepatitis E Virus</article-title>,” <source>Journal of Virology</source>
<volume>91</volume> (<year>2017</year>): <elocation-id>e02241‐16</elocation-id>.<pub-id pub-id-type="pmid">28202767</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1128/JVI.02241-16</pub-id><pub-id pub-id-type="pmcid">PMC5391457</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0003"><label>3</label><mixed-citation id="jvh70152-cit-0003" publication-type="journal">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Horn</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Hoodgarzadeh</surname>
</string-name>, <string-name name-style="western">
<given-names>C. J.</given-names>
<surname>Klett‐Tammen</surname>
</string-name>, <string-name name-style="western">
<given-names>R. T.</given-names>
<surname>Mikolajczyk</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Krause</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. J.</given-names>
<surname>Ott</surname>
</string-name>, “<article-title>Epidemiologic Estimates of Hepatitis E Virus Infection in European Countries</article-title>,” <source>Journal of Infection</source>
<volume>77</volume> (<year>2018</year>): <fpage>544</fpage>–<lpage>552</lpage>.<pub-id pub-id-type="pmid">30268515</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jinf.2018.09.012</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0004"><label>4</label><mixed-citation id="jvh70152-cit-0004" publication-type="journal">
<string-name name-style="western">
<given-names>T.</given-names>
<surname>Horvatits</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Schulze Zur Wiesch</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Lütgehetmann</surname>
</string-name>, <string-name name-style="western">
<given-names>A. W.</given-names>
<surname>Lohse</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Pischke</surname>
</string-name>, “<article-title>The Clinical Perspective on Hepatitis E</article-title>,” <source>Viruses</source>
<volume>11</volume> (<year>2019</year>): <elocation-id>617</elocation-id>.<pub-id pub-id-type="pmid">31284447</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/v11070617</pub-id><pub-id pub-id-type="pmcid">PMC6669652</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0005"><label>5</label><mixed-citation id="jvh70152-cit-0005" publication-type="journal">
<article-title>EASL Clinical Practice Guidelines on Hepatitis E Virus Infection</article-title>,” <source>Journal of Hepatology</source>
<volume>68</volume> (<year>2018</year>): <fpage>1256</fpage>–<lpage>1271</lpage>.<pub-id pub-id-type="pmid">29609832</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2018.03.005</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0006"><label>6</label><mixed-citation id="jvh70152-cit-0006" publication-type="journal">
<string-name name-style="western">
<given-names>G. H.</given-names>
<surname>Lee</surname>
</string-name>, <string-name name-style="western">
<given-names>B. H.</given-names>
<surname>Tan</surname>
</string-name>, <string-name name-style="western">
<given-names>E. C.</given-names>
<surname>Teo</surname>
</string-name>, et al., “<article-title>Chronic Infection With Camelid Hepatitis E Virus in a Liver Transplant Recipient Who Regularly Consumes Camel Meat and Milk</article-title>,” <source>Gastroenterology</source>
<volume>150</volume> (<year>2016</year>): <fpage>7.e3</fpage>–<lpage>7.e355</lpage>.<pub-id pub-id-type="pmid">26551551</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2015.10.048</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0007"><label>7</label><mixed-citation id="jvh70152-cit-0007" publication-type="journal">
<string-name name-style="western">
<given-names>D.</given-names>
<surname>Kogias</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Skeva</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Smyrlis</surname>
</string-name>, et al., “<article-title>Hepatitis E Virus (HEV) Infection in Hemodialysis Patients: A Multicenter Epidemiological Cohort Study in North‐Eastern Greece</article-title>,” <source>Pathogens</source>
<volume>12</volume> (<year>2023</year>): <elocation-id>667</elocation-id>.<pub-id pub-id-type="pmid">37242337</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/pathogens12050667</pub-id><pub-id pub-id-type="pmcid">PMC10222133</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0008"><label>8</label><mixed-citation id="jvh70152-cit-0008" publication-type="journal">
<string-name name-style="western">
<given-names>Z.</given-names>
<surname>Ma</surname>
</string-name>, <string-name name-style="western">
<given-names>R. A.</given-names>
<surname>de Man</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Kamar</surname>
</string-name>, and <string-name name-style="western">
<given-names>Q.</given-names>
<surname>Pan</surname>
</string-name>, “<article-title>Chronic Hepatitis E: Advancing Research and Patient Care</article-title>,” <source>Journal of Hepatology</source>
<volume>77</volume> (<year>2022</year>): <fpage>1109</fpage>–<lpage>1123</lpage>.<pub-id pub-id-type="pmid">35605741</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2022.05.006</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0009"><label>9</label><mixed-citation id="jvh70152-cit-0009" publication-type="journal">
<string-name name-style="western">
<given-names>D.</given-names>
<surname>Kogias</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Gavriilidis</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Antoniadou</surname>
</string-name>, et al., “<article-title>Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab</article-title>,” <source>Journal of Viral Hepatitis</source>
<volume>32</volume> (<year>2025</year>): <elocation-id>e70005</elocation-id>.<pub-id pub-id-type="pmid">39927678</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/jvh.70005</pub-id><pub-id pub-id-type="pmcid">PMC11809126</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0010"><label>10</label><mixed-citation id="jvh70152-cit-0010" publication-type="journal">
<string-name name-style="western">
<given-names>I.</given-names>
<surname>Parisi</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>O'Beirne</surname>
</string-name>, <string-name name-style="western">
<given-names>R. E.</given-names>
<surname>Rossi</surname>
</string-name>, et al., “<article-title>Elevated Liver Enzymes in Inflammatory Bowel Disease: The Role and Safety of Infliximab</article-title>,” <source>European Journal of Gastroenterology &amp; Hepatology</source>
<volume>28</volume> (<year>2016</year>): <fpage>786</fpage>–<lpage>791</lpage>.<pub-id pub-id-type="pmid">27015138</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MEG.0000000000000624</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0011"><label>11</label><mixed-citation id="jvh70152-cit-0011" publication-type="journal">
<string-name name-style="western">
<given-names>P. L.</given-names>
<surname>Valentino</surname>
</string-name>, <string-name name-style="western">
<given-names>B. M.</given-names>
<surname>Feldman</surname>
</string-name>, <string-name name-style="western">
<given-names>T. D.</given-names>
<surname>Walters</surname>
</string-name>, et al., “<article-title>Abnormal Liver Biochemistry Is Common in Pediatric Inflammatory Bowel Disease: Prevalence and Associations</article-title>,” <source>Inflammatory Bowel Diseases</source>
<volume>21</volume> (<year>2015</year>): <fpage>2848</fpage>–<lpage>2856</lpage>.<pub-id pub-id-type="pmid">26273817</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MIB.0000000000000558</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0012"><label>12</label><mixed-citation id="jvh70152-cit-0012" publication-type="journal">
<string-name name-style="western">
<given-names>F. D.</given-names>
<surname>Mendes</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Levy</surname>
</string-name>, <string-name name-style="western">
<given-names>F. B.</given-names>
<surname>Enders</surname>
</string-name>, <string-name name-style="western">
<given-names>E. V.</given-names>
<surname>Loftus Jr</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Angulo</surname>
</string-name>, and <string-name name-style="western">
<given-names>K. D.</given-names>
<surname>Lindor</surname>
</string-name>, “<article-title>Abnormal Hepatic Biochemistries in Patients With Inflammatory Bowel Disease</article-title>,” <source>American Journal of Gastroenterology</source>
<volume>102</volume> (<year>2007</year>): <fpage>344</fpage>–<lpage>350</lpage>.<pub-id pub-id-type="pmid">17100965</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/j.1572-0241.2006.00947.x</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0013"><label>13</label><mixed-citation id="jvh70152-cit-0013" publication-type="journal">
<string-name name-style="western">
<given-names>C.</given-names>
<surname>Senosiain</surname>
</string-name>, <string-name name-style="western">
<given-names>A. A.</given-names>
<surname>González‐Tallón</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>López‐Sanromán</surname>
</string-name>, et al., “<article-title>Hepatitis E Seroprevalence in Inflammatory Bowel Disease</article-title>,” <source>Gastroenterología y Hepatología</source>
<volume>39</volume> (<year>2016</year>): <fpage>185</fpage>–<lpage>190</lpage>.<pub-id pub-id-type="pmid">26257097</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.gastrohep.2015.06.004</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0014"><label>14</label><mixed-citation id="jvh70152-cit-0014" publication-type="journal">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Garrido</surname>
</string-name>, <string-name name-style="western">
<given-names>T.</given-names>
<surname>Guedes</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Abreu</surname>
</string-name>, et al., “<article-title>Ηepatitis E Seroprevalence in Portuguese Inflammatory Bowel Disease Patients Under Immunosuppression Is Higher Than Expected</article-title>,” <source>Journal of Crohn's and Colitis</source>
<volume>13</volume>, no. <issue>Suppl 1</issue> (<year>2019</year>): <fpage>S553</fpage>–<lpage>S554</lpage>.</mixed-citation></ref><ref id="jvh70152-bib-0015"><label>15</label><mixed-citation id="jvh70152-cit-0015" publication-type="journal">
<string-name name-style="western">
<given-names>P.</given-names>
<surname>Hoffmann</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Behnisch</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Gsenger</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Schnitzler</surname>
</string-name>, and <string-name name-style="western">
<given-names>A.</given-names>
<surname>Gauss</surname>
</string-name>, “<article-title>Hepatitis E Seroprevalence in a German Cohort of Patients With Inflammatory Bowel Diseases</article-title>,” <source>PLoS One</source>
<volume>15</volume> (<year>2020</year>): <elocation-id>e0239825</elocation-id>.<pub-id pub-id-type="pmid">33027305</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1371/journal.pone.0239825</pub-id><pub-id pub-id-type="pmcid">PMC7540852</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0016"><label>16</label><mixed-citation id="jvh70152-cit-0016" publication-type="journal">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Grigas</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Montoya</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Simkute</surname>
</string-name>, et al., “<article-title>Molecular Characterization and Seroprevalence of Hepatitis E Virus in Inflammatory Bowel Disease Patients and Solid Organ Transplant Recipients</article-title>,” <source>Viruses</source>
<volume>13</volume> (<year>2021</year>): <elocation-id>670</elocation-id>.<pub-id pub-id-type="pmid">33924409</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/v13040670</pub-id><pub-id pub-id-type="pmcid">PMC8070591</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0017"><label>17</label><mixed-citation id="jvh70152-cit-0017" publication-type="journal">
<string-name name-style="western">
<given-names>I.</given-names>
<surname>Kounis</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Renou</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Nahon</surname>
</string-name>, et al., “<article-title>Hepatitis E Virus Infection in Patients With Chronic Inflammatory Bowel Disease Treated With Immunosuppressive Therapy</article-title>,” <source>Pathogens</source>
<volume>12</volume> (<year>2023</year>): <elocation-id>332</elocation-id>.<pub-id pub-id-type="pmid">36839604</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/pathogens12020332</pub-id><pub-id pub-id-type="pmcid">PMC9966788</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0018"><label>18</label><mixed-citation id="jvh70152-cit-0018" publication-type="journal">
<string-name name-style="western">
<given-names>L.</given-names>
<surname>Santos</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Cavalcanti</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Mendes</surname>
</string-name>, et al., “<article-title>Prevalence of HEV Infection in HIV Carriers, Patients With Inflammatory Bowel Disease and Cirrhotic Patients</article-title>,” <source>Annals of Hepatology</source>
<volume>28</volume>, no. <issue>Suppl 1</issue> (<year>2023</year>): <elocation-id>100904</elocation-id>.</mixed-citation></ref><ref id="jvh70152-bib-0019"><label>19</label><mixed-citation id="jvh70152-cit-0019" publication-type="journal">
<string-name name-style="western">
<given-names>E. B.</given-names>
<surname>Haagsma</surname>
</string-name>, <string-name name-style="western">
<given-names>A. P.</given-names>
<surname>van den Berg</surname>
</string-name>, <string-name name-style="western">
<given-names>R. J.</given-names>
<surname>Porte</surname>
</string-name>, et al., “<article-title>Chronic Hepatitis E Virus Infection in Liver Transplant Recipients</article-title>,” <source>Liver Transplantation</source>
<volume>14</volume> (<year>2008</year>): <fpage>547</fpage>–<lpage>553</lpage>.<pub-id pub-id-type="pmid">18383084</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/lt.21480</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0020"><label>20</label><mixed-citation id="jvh70152-cit-0020" publication-type="journal">
<string-name name-style="western">
<given-names>B.</given-names>
<surname>Taton</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Moreau</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Lepreux</surname>
</string-name>, et al., “<article-title>Hepatitis E Virus Infection as a New Probable Cause of de Novo Membranous Nephropathy After Kidney Transplantation</article-title>,” <source>Transplant Infectious Disease</source>
<volume>15</volume> (<year>2013</year>): <fpage>E211</fpage>–<lpage>E215</lpage>.<pub-id pub-id-type="pmid">24103101</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/tid.12143</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0021"><label>21</label><mixed-citation id="jvh70152-cit-0021" publication-type="journal">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Aherfi</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Borentain</surname>
</string-name>, <string-name name-style="western">
<given-names>F.</given-names>
<surname>Raissouni</surname>
</string-name>, et al., “<article-title>Liver Transplantation for Acute Liver Failure Related to Autochthonous Genotype 3 Hepatitis E Virus Infection</article-title>,” <source>Clinics and Research in Hepatology and Gastroenterology</source>
<volume>38</volume> (<year>2014</year>): <fpage>24</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">24462173</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.clinre.2013.05.013</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0022"><label>22</label><mixed-citation id="jvh70152-cit-0022" publication-type="journal">
<string-name name-style="western">
<given-names>C. M.</given-names>
<surname>Nijskens</surname>
</string-name>, <string-name name-style="western">
<given-names>S. D.</given-names>
<surname>Pas</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Cornelissen</surname>
</string-name>, et al., “<article-title>Hepatitis E Virus Genotype 3 Infection in a Tertiary Referral Center in The Netherlands: Clinical Relevance and Impact on Patient Morbidity</article-title>,” <source>Journal of Clinical Virology</source>
<volume>74</volume> (<year>2016</year>): <fpage>82</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">26687439</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jcv.2015.11.038</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0023"><label>23</label><mixed-citation id="jvh70152-cit-0023" publication-type="journal">
<string-name name-style="western">
<given-names>K.</given-names>
<surname>Suzuki</surname>
</string-name>, <string-name name-style="western">
<given-names>I.</given-names>
<surname>Kumagai</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Yoshida</surname>
</string-name>, et al., “<article-title>Asymptomatic Acute Hepatitis E in a Female Patient With Ulcerative Colitis</article-title>,” <source>Clinical Journal of Gastroenterology</source>
<volume>10</volume> (<year>2017</year>): <fpage>255</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">28353200</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12328-017-0730-7</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0024"><label>24</label><mixed-citation id="jvh70152-cit-0024" publication-type="journal">
<string-name name-style="western">
<given-names>A. E. M.</given-names>
<surname>Robins</surname>
</string-name>, <string-name name-style="western">
<given-names>D. J.</given-names>
<surname>Bowden</surname>
</string-name>, and <string-name name-style="western">
<given-names>W. T. H.</given-names>
<surname>Gelson</surname>
</string-name>, “<article-title>Chronic Genotype 1 Hepatitis E Infection From Immunosuppression for Ileo‐Colonic Crohn's Disease</article-title>,” <source>Oxford Medical Case Reports</source>
<volume>2018</volume> (<year>2018</year>): <elocation-id>omy059</elocation-id>.<pub-id pub-id-type="pmid">30159153</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/omcr/omy059</pub-id><pub-id pub-id-type="pmcid">PMC6109198</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0025"><label>25</label><mixed-citation id="jvh70152-cit-0025" publication-type="journal">
<string-name name-style="western">
<given-names>C.</given-names>
<surname>Charre</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Ramière</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Dumortier</surname>
</string-name>, et al., “<article-title>Chronic Genotype 3 Hepatitis E in Pregnant Woman Receiving Infliximab and Azathioprine</article-title>,” <source>Emerging Infectious Diseases</source>
<volume>24</volume> (<year>2018</year>): <fpage>941</fpage>–<lpage>943</lpage>.<pub-id pub-id-type="pmid">29664396</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3201/eid2405.171845</pub-id><pub-id pub-id-type="pmcid">PMC5938778</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0026"><label>26</label><mixed-citation id="jvh70152-cit-0026" publication-type="journal">
<string-name name-style="western">
<given-names>R. L.</given-names>
<surname>Goetgebuer</surname>
</string-name>, <string-name name-style="western">
<given-names>G. M. C.</given-names>
<surname>Masclee</surname>
</string-name>, <string-name name-style="western">
<given-names>A. A.</given-names>
<surname>van der Eijk</surname>
</string-name>, <string-name name-style="western">
<given-names>C. J.</given-names>
<surname>van der Woude</surname>
</string-name>, <string-name name-style="western">
<given-names>R. A.</given-names>
<surname>de Man</surname>
</string-name>, and <string-name name-style="western">
<given-names>A. C.</given-names>
<surname>de Vries</surname>
</string-name>, “<article-title>Hepatitis E Infection With a Benign Course During Vedolizumab Treatment for Crohn's Disease: A Case Report</article-title>,” <source>Clinical Research in Hepatology and Gastroenterology</source>
<volume>46</volume> (<year>2022</year>): <elocation-id>101948</elocation-id>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.clinre.2022.101948</pub-id><pub-id pub-id-type="pmid">35659604</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0027"><label>27</label><mixed-citation id="jvh70152-cit-0027" publication-type="journal">
<string-name name-style="western">
<given-names>M. J.</given-names>
<surname>Page</surname>
</string-name>, <string-name name-style="western">
<given-names>J. E.</given-names>
<surname>McKenzie</surname>
</string-name>, <string-name name-style="western">
<given-names>P. M.</given-names>
<surname>Bossuyt</surname>
</string-name>, et al., “<article-title>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</article-title>,” <source>BMJ</source>
<volume>372</volume> (<year>2021</year>): <elocation-id>n71</elocation-id>.<pub-id pub-id-type="pmid">33782057</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0028"><label>28</label><mixed-citation id="jvh70152-cit-0028" publication-type="journal">
<string-name name-style="western">
<given-names>P.</given-names>
<surname>Li</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Liu</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, et al., “<article-title>The Global Epidemiology of Hepatitis E Virus Infection: A Systematic Review and Meta‐Analysis</article-title>,” <source>Liver International</source>
<volume>40</volume> (<year>2020</year>): <fpage>1516</fpage>–<lpage>1528</lpage>.<pub-id pub-id-type="pmid">32281721</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.14468</pub-id><pub-id pub-id-type="pmcid">PMC7384095</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0029"><label>29</label><mixed-citation id="jvh70152-cit-0029" publication-type="journal">
<string-name name-style="western">
<given-names>G.</given-names>
<surname>Buescher</surname>
</string-name>, <string-name name-style="western">
<given-names>A. K.</given-names>
<surname>Ozga</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Lorenz</surname>
</string-name>, et al., “<article-title>Hepatitis E Seroprevalence and Viremia Rate in Immunocompromised Patients: A Systematic Review and Meta‐Analysis</article-title>,” <source>Liver International</source>
<volume>41</volume> (<year>2021</year>): <fpage>449</fpage>–<lpage>455</lpage>.<pub-id pub-id-type="pmid">33034121</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.14695</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0030"><label>30</label><mixed-citation id="jvh70152-cit-0030" publication-type="journal">
<string-name name-style="western">
<given-names>L. L.</given-names>
<surname>Ma</surname>
</string-name>, <string-name name-style="western">
<given-names>Y. Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name name-style="western">
<given-names>Z. H.</given-names>
<surname>Yang</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Huang</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Weng</surname>
</string-name>, and <string-name name-style="western">
<given-names>X. T.</given-names>
<surname>Zeng</surname>
</string-name>, “<article-title>Methodological Quality (Risk of Bias) Assessment Tools for Primary and Secondary Medical Studies: What Are They and Which Is Better?</article-title>,” <source>Military Medical Research</source>
<volume>7</volume> (<year>2020</year>): <elocation-id>7</elocation-id>.<pub-id pub-id-type="pmid">32111253</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s40779-020-00238-8</pub-id><pub-id pub-id-type="pmcid">PMC7049186</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0031"><label>31</label><mixed-citation id="jvh70152-cit-0031" publication-type="journal">
<string-name name-style="western">
<given-names>J. F.</given-names>
<surname>Rahier</surname>
</string-name>, <string-name name-style="western">
<given-names>F.</given-names>
<surname>Magro</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Abreu</surname>
</string-name>, et al., “<article-title>Second European Evidence‐Based Consensus on the Prevention, Diagnosis and Management of Opportunistic Infections in Inflammatory Bowel Disease</article-title>,” <source>Journal of Crohn's and Colitis</source>
<volume>8</volume> (<year>2014</year>): <fpage>443</fpage>–<lpage>468</lpage>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.crohns.2013.12.013</pub-id><pub-id pub-id-type="pmid">24613021</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0032"><label>32</label><mixed-citation id="jvh70152-cit-0032" publication-type="journal">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Naganuma</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Kunisaki</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Yoshimura</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Takeuchi</surname>
</string-name>, and <string-name name-style="western">
<given-names>M.</given-names>
<surname>Watanabe</surname>
</string-name>, “<article-title>A Prospective Analysis of the Incidence of and Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease</article-title>,” <source>Journal of Gastroenterology</source>
<volume>48</volume> (<year>2013</year>): <fpage>595</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">23053426</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00535-012-0686-9</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0033"><label>33</label><mixed-citation id="jvh70152-cit-0033" publication-type="journal">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Bonovas</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Fiorino</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Allocca</surname>
</string-name>, et al., “<article-title>Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta‐Analysis</article-title>,” <source>Clinical Gastroenterology and Hepatology</source>
<volume>14</volume> (<year>2016</year>): <fpage>1385</fpage>–<lpage>1397.e10</lpage>.<pub-id pub-id-type="pmid">27189910</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cgh.2016.04.039</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0034"><label>34</label><mixed-citation id="jvh70152-cit-0034" publication-type="journal">
<string-name name-style="western">
<given-names>E. D.</given-names>
<surname>Shah</surname>
</string-name>, <string-name name-style="western">
<given-names>J. P.</given-names>
<surname>Farida</surname>
</string-name>, <string-name name-style="western">
<given-names>C. A.</given-names>
<surname>Siegel</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Chong</surname>
</string-name>, and <string-name name-style="western">
<given-names>G. Y.</given-names>
<surname>Melmed</surname>
</string-name>, “<article-title>Risk for Overall Infection With Anti‐TNF and Anti‐Integrin Agents Used in IBD: A Systematic Review and Meta‐Analysis</article-title>,” <source>Inflammatory Bowel Diseases</source>
<volume>23</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>570</fpage>–<lpage>577</lpage>.<pub-id pub-id-type="pmid">28230558</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MIB.0000000000001049</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0035"><label>35</label><mixed-citation id="jvh70152-cit-0035" publication-type="journal">
<string-name name-style="western">
<given-names>C. L.</given-names>
<surname>Wheat</surname>
</string-name>, <string-name name-style="western">
<given-names>C. W.</given-names>
<surname>Ko</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Clark‐Snustad</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Grembowski</surname>
</string-name>, <string-name name-style="western">
<given-names>T. A.</given-names>
<surname>Thornton</surname>
</string-name>, and <string-name name-style="western">
<given-names>B.</given-names>
<surname>Devine</surname>
</string-name>, “<article-title>Inflammatory Bowel Disease (IBD) Pharmacotherapy and the Risk of Serious Infection: A Systematic Review and Network Meta‐Analysis</article-title>,” <source>BMC Gastroenterology</source>
<volume>17</volume> (<year>2017</year>): <elocation-id>52</elocation-id>.<pub-id pub-id-type="pmid">28407755</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s12876-017-0602-0</pub-id><pub-id pub-id-type="pmcid">PMC5391579</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0036"><label>36</label><mixed-citation id="jvh70152-cit-0036" publication-type="journal">
<string-name name-style="western">
<given-names>D.</given-names>
<surname>Lenggenhager</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Pawel</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Honcharova‐Biletska</surname>
</string-name>, et al., “<article-title>The Histologic Presentation of Hepatitis E Reflects Patients' Immune Status and Pre‐Existing Liver Condition</article-title>,” <source>Modern Pathology</source>
<volume>34</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>233</fpage>–<lpage>248</lpage>.<pub-id pub-id-type="pmid">32572157</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41379-020-0593-1</pub-id><pub-id pub-id-type="pmcid">PMC7806507</pub-id></mixed-citation></ref><ref id="jvh70152-bib-0037"><label>37</label><mixed-citation id="jvh70152-cit-0037" publication-type="journal">
<string-name name-style="western">
<given-names>R.</given-names>
<surname>Alexandrova</surname>
</string-name>, <string-name name-style="western">
<given-names>I.</given-names>
<surname>Tsachev</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Kirov</surname>
</string-name>, et al., “<article-title>Hepatitis E Virus (HEV) Infection Among Immunocompromised Individuals: A Brief Narrative Review</article-title>,” <source>Infection and Drug Resistance</source>
<volume>17</volume> (<year>2024</year>): <fpage>1021</fpage>–<lpage>1040</lpage>.<pub-id pub-id-type="pmid">38505248</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/IDR.S449221</pub-id><pub-id pub-id-type="pmcid">PMC10948336</pub-id></mixed-citation></ref></ref-list></back></article>